Physician profile
Mark G Bowling
NPI 1982657219
$7,207.80
in general payments reported to CMS, 2019-2025
46 companies · $1,451 in 2025
The $1,451 reported for 2025 was more than what 92% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,078 · 2020: $910 · 2021: $1,296 · 2022: $550 · 2023: $811 · 2024: $1,112 · 2025: $1,451.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,373.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,373.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,159.82 | 2019-2025 | Vraylar, Ubrelvy, Qulipta |
| Novo Nordisk INC | $1,102.51 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $502.97 | 2019-2025 | Evenity, Repatha, Krystexxa |
| Lilly USA, LLC | $501.06 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $484.17 | 2019-2025 | |
| Glaxosmithkline, LLC. | $341.67 | 2019-2025 | Trelegy Ellipta, Shingrix, Bexsero |
| Amarin Pharma, INC. | $341.42 | 2019-2022 | |
| Abbott Laboratories | $278.24 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $263.28 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Sanofi-Aventis U.S. LLC | $252.04 | 2019-2021 | |
| Astrazeneca Pharmaceuticals Lp | $235.70 | 2019-2024 | Farxiga |
| Takeda Pharmaceuticals U.S.A., INC. | $194.54 | 2019-2023 | Gattex |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $172.25 | 2019-2025 | Xifaxan |
| Vanda Pharmaceuticals INC. | $171.53 | 2025 | Fanapt, Hetlioz |
| Janssen Pharmaceuticals, INC | $99.84 | 2019-2022 |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Bowling listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.